NCT06053580View on ClinicalTrials.gov

Repurposing Valsartan May Protect Against Pulmonary Hypertension

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 28, 2024

Primary Completion Date

July 1, 2027

Study Completion Date

July 1, 2027

Conditions
Pulmonary Arterial HypertensionRight Heart FailureRight Ventricular DysfunctionPulmonary Vascular Disorder
Interventions
DRUG

Valsartan 40 mg

Valsartan 40mg twice daily for 24 weeks.

DRUG

Placebo

Placebo twice daily for 24 weeks.

Trial Locations (1)

98195

RECRUITING

University of Washington Medical Center, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

University of Washington

OTHER